On June 15, 2020, the U.S. Food and Drug Administration (FDA) granted marketing approval to Akili Interactive for its game-based prescription digital therapeutic, EndeavorRx, to improve attention function in children with attention deficit/hyperactivity disorder (ADHD). It is the first prescription digital therapeutic intended to improve symptoms associated with ADHD, as well as the first prescription therapeutic with a video game-like interface to be granted marketing authorization by the FDA for any type of condition. The same day as the FDA approval, Akili announced that EndeavorRx treatment will be available with a prescription in the near future . . .